Comparative Immunogenicity of Evolved V1V2-Deleted HIV-1 Envelope Glycoprotein Trimers

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Bontjer, Ilja ^a   Melchers, Mark ^a   Tong, Tommy ^b   van Montfort, Thijs ^a   Eggink, Dirk ^a   Montefiori, David ^c   Olson, William C ^d   Moore, John P ^e   Binley, James M ^b   Berkhout, Ben ^a   Sanders, Rogier W ^a,e  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b TORREY PINES INSTITUTE FOR MOLECULAR STUDIES   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d A Subsidiary of Lantheus Holdings   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 140; UNCLASSIFIED DRUG; V1V2 PROTEIN; VIRUS ENVELOPE PROTEIN; VIRUS PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; EMBRYO; ENVELOPE GENE; GENE DELETION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; HYDROPHOBICITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MOLECULAR EVOLUTION; NONHUMAN; POLYMERIZATION; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN INTERACTION; PROTEIN STABILITY; RABBIT; VIRUS MUTANT; VIRUS NEUTRALIZATION; ANIMAL; ANTIBODY PRODUCTION; BLOOD; CHEMISTRY; GENETICS; HIV INFECTIONS; IMMUNOLOGY; LEPORIDAE; SERODIAGNOSIS; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1; ORYCTOLAGUS CUNICULUS;

AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODY FORMATION; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; EPITOPES; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; NEUTRALIZATION TESTS; RABBITS; SEQUENCE DELETION;

EID: 84879471170     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067484     Document Type: Article

References (67)

1. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al. (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209-2220.
2. Dolin R, (2009) HIV vaccine trial results-an opening for further research. N Engl J Med 361: 2279-2280.
3. Johnson RP, Desrosiers RC, (1998) Protective immunity induced by live attenuated simian immunodeficiency virus. Curr Opin Immunol 10: 436-443.
4. Blower SM, Koelle K, Kirschner DE, Mills J, (2001) Live attenuated HIV vaccines: predicting the tradeoff between efficacy and safety. Proc Natl Acad Sci U S A 98: 3618-3623.
5. Reynolds MR, Weiler AM, Weisgrau KL, Piaskowski SM, Furlott JR, et al. (2008) Macaques vaccinated with live-attenuated SIV control replication of heterologous virus. J Exp Med 205: 2537-2550.
6. Koff WC, Johnson PR, Watkins DI, Burton DR, Lifson JD, et al. (2006) HIV vaccine design: insights from live attenuated SIV vaccines. Nat Immunol 7: 19-23.
7. Letvin NL, Barouch DH, Montefiori DC, (2002) Prospects for vaccine protection against HIV-1 infection and AIDS. Annu Rev Immunol 20: 73-99.
8. Broomall EM, Reynolds SM, Jacobson RM, (2010) Epidemiology, clinical manifestations, and recent advances in vaccination against human papillomavirus. Postgrad Med 122: 121-129.
9. McAleer WJ, Buynak EB, Maigetter RZ, Wampler DE, Miller WJ, et al. (1984) Human hepatitis B vaccine from recombinant yeast. Nature 307: 178-180.
10. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, et al. (2005) Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 191: 654-665.
11. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, et al. (2006) Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 194: 1661-1671.
12. Gilbert PB, Peterson ML, Follmann D, Hudgens MG, Francis DP, et al. (2005) Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis 191: 666-677.
13. Mascola JR, Montefiori DC, (2010) The role of antibodies in HIV vaccines. Annu Rev Immunol 28: 413-444.
14. Crooks ET, Tong T, Osawa K, Binley JM, (2011) Enzyme digests eliminate nonfunctional Env from HIV-1 particle surfaces, leaving native Env trimers intact and viral infectivity unaffected. J Virol 85: 5825-5839.
15. Moore PL, Crooks ET, Porter L, Zhu P, Cayanan CS, et al. (2006) Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol 80: 2515-2528.
16. Parren PW, Gauduin MC, Koup RA, Poignard P, Fisicaro P, et al. (1997) Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design. Immunol Lett 57: 105-112.
17. Parren PW, Sattentau QJ, Burton DR, (1997) HIV-1 antibody-debris or virion? Nat Med 3: 366-367.
18. Julien JP, Lee JH, Cupo A, Murin CD, Derking R, et al. (2013) Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proc Natl Acad Sci U S A 110: 4351-4356.
19. McLellan JS, Pancera M, Carrico C, Gorman J, Julien JP, et al. (2011) Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 480: 336-343.
20. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, et al. (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326: 285-289.
21. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, et al. (2012) Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 366: 1275-1286.
22. Rolland M, Edlefsen PT, Larsen BB, Tovanabutra S, Sanders-Buell E, et al. (2012) Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 490: 417-420.
23. Reitter JN, Means RE, Desrosiers RC, (1998) A role for carbohydrates in immune evasion in AIDS. Nat Med 4: 679-684.
24. Wei X, Decker JM, Wang S, Hui H, Kappes JC, et al. (2003) Antibody neutralization and escape by HIV-1. Nature 422: 307-312.
25. Depetris RS, Julien JP, Khayat R, Lee JH, Pejchal R, et al. (2012) Partial enzymatic deglycosylation preserves the structure of cleaved recombinant HIV-1 envelope glycoprotein trimers. J Biol Chem 287: 24239-24254.
26. Leonard CK, Spellman MW, Riddle L, Harris RJ, Thomas JN, et al. (1990) Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J Biol Chem 265: 10373-10382.
27. Pejchal R, Doores KJ, Walker LM, Khayat R, Huang PS, et al. (2011) A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 334: 1097-1103.
28. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, et al. (2011) Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477: 466-470.
29. Banerjee K, Andjelic S, Klasse PJ, Kang Y, Sanders RW, et al. (2009) Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo. Virology 389: 108-121.
30. Chung NP, Matthews K, Klasse PJ, Sanders RW, Moore JP, (2012) HIV-1 gp120 impairs the induction of B cell responses by TLR9-activated plasmacytoid dendritic cells. J Immunol 189: 5257-5265.
31. Martinelli E, Cicala C, Van Ryk D, Goode DJ, Macleod K, et al. (2007) HIV-1 gp120 inhibits TLR9-mediated activation and IFN-{alpha} secretion in plasmacytoid dendritic cells. Proc Natl Acad Sci U S A 104: 3396-3401.
32. Shan M, Klasse PJ, Banerjee K, Dey AK, Iyer SP, et al. (2007) HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells. PLoS Pathog 3: e169.
33. Binley JM, Sanders RW, Clas B, Schuelke N, Master A, et al. (2000) A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J Virol 74: 627-643.
34. Sanders RW, Vesanen M, Schuelke N, Master A, Schiffner L, et al. (2002) Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol 76: 8875-8889.
35. Binley JM, Sanders RW, Master A, Cayanan CS, Wiley CL, et al. (2002) Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins. J Virol 76: 2606-2616.
36. Gzyl J, Bolesta E, Wierzbicki A, Kmieciak D, Naito T, et al. (2004) Effect of partial and complete variable loop deletions of the human immunodeficiency virus type 1 envelope glycoprotein on the breadth of gp160-specific immune responses. Virology 318: 493-506.
37. Barnett SW, Lu S, Srivastava I, Cherpelis S, Gettie A, et al. (2001) The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J Virol 75: 5526-5540.
38. Jeffs SA, Shotton C, Balfe P, McKeating JA, (2002) Truncated gp120 envelope glycoprotein of human immunodeficiency virus 1 elicits a broadly reactive neutralizing immune response. J Gen Virol 83: 2723-2732.
39. Lu S, Wyatt R, Richmond JF, Mustafa F, Wang S, et al. (1998) Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions. AIDS Res Hum Retroviruses 14: 151-155.
40. Bontjer I, Land A, Eggink D, Verkade E, Tuin K, et al. (2009) Optimization of human immunodeficiency virus type 1 envelope glycoproteins with V1/V2 deleted, using virus evolution. J Virol 83: 368-383.
41. Bontjer I, Melchers M, Eggink D, David K, Moore JP, et al. (2010) Stabilized HIV-1 envelope glycoprotein trimers lacking the V1V2 domain, obtained by virus evolution. J Biol Chem 285: 36456-36470.
42. Center RJ, Schuck P, Leapman RD, Arthur LO, Earl PL, et al (2001) Oligomeric structure of virion-associated and soluble forms of the simian immunodeficiency virus envelope protein in the prefusion activated conformation. Proc Natl Acad Sci U S A 98: 14877-14882.
43. Sanders RW, Schiffner L, Master A, Kajumo F, Guo Y, et al. (2000) Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits. J Virol 74: 5091-5100.
44. Schulke N, Vesanen MS, Sanders RW, Zhu P, Lu M, et al. (2002) Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein. J Virol 76: 7760-7776.
45. Wyatt R, Sullivan N, Thali M, Repke H, Ho D, et al. (1993) Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions. J Virol 67: 4557-4565.
46. Pollard SR, Rosa MD, Rosa JJ, Wiley DC, (1992) Truncated variants of gp120 bind CD4 with high affinity and suggest a minimum CD4 binding region. EMBO J 11: 585-591.
47. Travis BM, Dykers TI, Hewgill D, Ledbetter J, Tsu TT, et al. (1992) Functional roles of the V3 hypervariable region of HIV-1 gp160 in the processing of gp160 and in the formation of syncytia in CD4+ cells. Virology 186: 313-317.
48. Chiou SH, Freed EO, Panganiban AT, Kenealy WR, (1992) Studies on the role of the V3 loop in human immunodeficiency virus type 1 envelope glycoprotein function. AIDS Res Hum Retroviruses 8: 1611-1618.
49. Eggink D, Melchers M, Wuhrer M, van Montfort T, Dey AK, et al. (2010) Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry function. Virology 401: 236-247.
50. Melchers M, Bontjer I, Tong T, Chung NP, Klasse PJ, et al. (2012) Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses. J Virol 86: 2488-2500.
51. Melchers M, Matthews K, de Vries RP, Eggink D, van Montfort T, et al. (2011) A stabilized HIV-1 envelope glycoprotein trimer fused to CD40 ligand targets and activates dendritic cells. Retrovirology 8: 48.
52. Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, et al. (2004) HIV vaccine design and the neutralizing antibody problem. Nat Immunol 5: 233-236.
53. Popkov M, Mage RG, Alexander CB, Thundivalappil S, Barbas CF 3rd, et al (2003) Rabbit immune repertoires as sources for therapeutic monoclonal antibodies: the impact of kappa allotype-correlated variation in cysteine content on antibody libraries selected by phage display. J Mol Biol 325: 325-335.
54. Beddows S, Schulke N, Kirschner M, Barnes K, Franti M, et al. (2005) Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol 79: 8812-8827.
55. Binley JM, Wrin T, Korber B, Zwick MB, Wang M, et al. (2004) Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 78: 13232-13252.
56. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, et al. (2005) Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 79: 10108-10125.
57. Cao J, Sullivan N, Desjardin E, Parolin C, Robinson J, et al. (1997) Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein. J Virol 71: 9808-9812.
58. Jeffs SA, McKeating J, Lewis S, Craft H, Biram D, et al. (1996) Antigenicity of truncated forms of the human immunodeficiency virus type 1 envelope glycoprotein. J Gen Virol 77 (Pt 7): 1403-1410.
59. Lu YC, Touzjian N, Stenzel M, Dorfman T, Sodroski JG, et al. (1990) Identification of cis-acting repressive sequences within the negative regulatory element of human immunodeficiency virus type 1. J Virol 64: 5226-5229.
60. Srivastava IK, Stamatatos L, Kan E, Vajdy M, Lian Y, et al. (2003) Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate. J Virol 77: 11244-11259.
61. Bonsignori M, Hwang KK, Chen X, Tsao CY, Morris L, et al. (2011) Analysis of a Clonal Lineage of HIV-1 Envelope V2/V3 Conformational Epitope-Specific Broadly Neutralizing Antibodies and Their Inferred Unmutated Common Ancestors. J Virol.
62. Rusert P, Krarup A, Magnus C, Brandenberg OF, Weber J, et al. (2011) Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies. J Exp Med 208: 1419-1433.
63. Hu G, Liu J, Taylor KA, Roux KH, (2011) Structural comparison of HIV-1 envelope spikes with and without the V1/V2 loop. J Virol 85: 2741-2750.
64. Ward AB (2013) Evaluating HIV Envelope Trimers as Structural Scaffolds and Immunogens. HIV vaccines, Keystone Symposia. Keystone, Colorado, US.
65. Dey AK, David KB, Lu M, Moore JP, (2009) Biochemical and biophysical comparison of cleaved and uncleaved soluble, trimeric HIV-1 envelope glycoproteins. Virology 385: 275-281.
66. Trkola A, Dragic T, Arthos J, Binley JM, Olson WC, et al. (1996) CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 384: 184-187.
67. Crooks ET, Jiang P, Franti M, Wong S, Zwick MB, et al. (2008) Relationship of HIV-1 and SIV envelope glycoprotein trimer occupation and neutralization. Virology 377: 364-378.